🇺🇸 FDA
Patent

US 7635683

Quinoxalinyl tripeptide hepatitis C virus inhibitors

granted A61KA61K38/00

Quick answer

US patent 7635683 (Quinoxalinyl tripeptide hepatitis C virus inhibitors) held by Enanta Pharmaceuticals, Inc. expires Mon Dec 17 2029 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Enanta Pharmaceuticals, Inc.
Grant date
Tue Dec 22 2009 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Dec 17 2029 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
5
CPC classes
A61K, A61K38/00